Association of liver related biomarkers with incident cardiovascular disease and all-cause mortality in the Hispanic community health study/study of Latinos (HCHS/SOL), a population-based cohort study

Abstract Background Metabolic dysfunction-associated steatotic liver disease (MASLD) increases risk of cardiovascular disease (CVD). Despite the high prevalence of MASLD among Hispanic populations, there is a scarcity of research on the associations between non-invasive markers of liver disease and...

Full description

Saved in:
Bibliographic Details
Main Authors: Mario Jesus Trejo, James S. Floyd, Daniele Massera, Martha Daviglus, Olga Garcia-Bedoya, Jianwen Cai, Gregory A. Talavera, Dorathy E. Tamayo-Murillo, Daniel Labovitz, Robert Kaplan
Format: Article
Language:English
Published: BMC 2025-07-01
Series:BMC Gastroenterology
Subjects:
Online Access:https://doi.org/10.1186/s12876-025-04133-1
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Metabolic dysfunction-associated steatotic liver disease (MASLD) increases risk of cardiovascular disease (CVD). Despite the high prevalence of MASLD among Hispanic populations, there is a scarcity of research on the associations between non-invasive markers of liver disease and incident CVD and all-cause mortality. In this study we investigated the association of liver related biomarkers with CVD events and all-cause mortality in a population based Hispanic/Latino cohort. Methods We included 15,216 participants from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) aged 18–74 years with no pre-existing CVD. The composite outcome combined incident CVD and all-cause mortality. Having “elevated ALT/AST” was defined as ALT > 40 IU/mL or AST > 37 IU/mL for males, and ALT or AST > 31 IU/mL for females. We estimated adjusted hazard ratios (HR) and 95% confidence intervals (CI) relating our composite outcome to elevated ALT/AST, FIB-4 and MASLD. Using interaction terms, we assessed whether the relationship between elevated ALT/AST and the composite outcome differed by MASLD status. Results The study population was 40 years old on average, 52.7% female and had 740 CVD or all-cause mortality events. Elevated FIB-4 had the strongest association with incident CVD or all-cause mortality (comparing FIB-4 > 2.67 versus ≤ 2.67, HR:3.47; CI:2.34–5.14). Elevated AST was found to be associated with incident CVD or all-cause mortality (HR:1.53; CI:1.14–2.05). MASLD was not associated with incident CVD or all-cause mortality (HR:1.14; CI: 0.94–1.40), but it was associated with incident CVD alone (HR:1.69; CI:1.19–2.39). The relationship between elevated ALT/AST and incident or all-cause mortality was modified by MASLD, such that the strongest association between elevated ALT/AST and incident CVD or all-cause mortality was in the absence of MASLD (HR:1.95; CI:1.20–3.18). Conclusions Among Hispanic adults FIB-4 was strongly associated with CVD or all-cause mortality and among persons without MASLD, elevated ALT/AST were associated with CVD or all-cause mortality.
ISSN:1471-230X